A team of Ballard Spahr attorneys represented Cephalon in its acquisition of cancer therapeutics developer Gemin X for $225 million in cash on a cash-free, debt-free basis. The deal, expected to close in the second quarter of 2011, also involves the possibility of Gemin's stockholders receiving up to $300 million in cash payments if it attains a number of regulatory and sales objectives.